Table 3 Important combinational studies for Ph− ALL
From: Recent updates for antibody therapy for acute lymphoblastic leukemia
Type | Frontline Ph− ALL | R/R Ph− ALL | |||
|---|---|---|---|---|---|
Ref | [64] | [65] | [66] | [67] | [68] |
Rigemen | Sequential hyper-CVAD + BLN | Mini-HCVD + IO ± BLN | SWOG 1318: BLN + POMP | SWOG 1312: CVP + IO | Mini-HCVD + IO ± BLN |
Capicity | 27 | 64 | 31 | 48 | 84 |
Conditions | – | – | – | 44% Salvage 1 38% Prior BLN 19% Prior HSCT | 13% Primary refractory 40% CR1 duration  < 1 year 23% Prior HSCT |
Median age [range] | 38 [18–59] | 68 [60–81] | 73 [66–84] | 43 [20–79] | 35 [9–87] |
Response (CR/CRi) | 100% | 98% | 66% | 61% | 80% |
MRD negativity by flow cytometry | 96% | 95% | 92% | – | 80% |
Duration | RFS 76% at 1 year | 76% at 3 years | DFS 56% at 1 year | – | 52% at 2 years |
OS rate | 89% at 1Â year | 54% at 1Â years | 65% at 1Â year | Median 10.9Â months | 39% at 2Â years |